4pqw: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Crystal Structure of Phospholipase C beta 3 in Complex with PDZ1 of NHERF1== | ==Crystal Structure of Phospholipase C beta 3 in Complex with PDZ1 of NHERF1== | ||
<StructureSection load='4pqw' size='340' side='right' caption='[[4pqw]], [[Resolution|resolution]] 1.47Å' scene=''> | <StructureSection load='4pqw' size='340' side='right'caption='[[4pqw]], [[Resolution|resolution]] 1.47Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[4pqw]] is a 1 chain structure with sequence from [ | <table><tr><td colspan='2'>[[4pqw]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4PQW OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4PQW FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=NI:NICKEL+(II)+ION'>NI</scene> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=NI:NICKEL+(II)+ION'>NI</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4pqw FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4pqw OCA], [https://pdbe.org/4pqw PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4pqw RCSB], [https://www.ebi.ac.uk/pdbsum/4pqw PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4pqw ProSAT]</span></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | |||
</table> | </table> | ||
== Disease == | == Disease == | ||
[ | [https://www.uniprot.org/uniprot/NHRF1_HUMAN NHRF1_HUMAN] Defects in SLC9A3R1 are the cause of hypophosphatemic nephrolithiasis/osteoporosis type 2 (NPHLOP2) [MIM:[https://omim.org/entry/612287 612287]. Hypophosphatemia results from idiopathic renal phosphate loss. It contributes to the pathogenesis of hypophosphatemic urolithiasis (formation of urinary calculi) as well to that of hypophosphatemic osteoporosis (bone demineralization).<ref>PMID:18784102</ref> <ref>PMID:22506049</ref> | ||
== Function == | == Function == | ||
[ | [https://www.uniprot.org/uniprot/NHRF1_HUMAN NHRF1_HUMAN] Scaffold protein that connects plasma membrane proteins with members of the ezrin/moesin/radixin family and thereby helps to link them to the actin cytoskeleton and to regulate their surface expression. Necessary for recycling of internalized ADRB2. Was first known to play a role in the regulation of the activity and subcellular location of SLC9A3. Necessary for cAMP-mediated phosphorylation and inhibition of SLC9A3. May enhance Wnt signaling. May participate in HTR4 targeting to microvilli (By similarity). Involved in the regulation of phosphate reabsorption in the renal proximal tubules.<ref>PMID:9430655</ref> <ref>PMID:9096337</ref> <ref>PMID:10499588</ref> <ref>PMID:18784102</ref> | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
| Line 21: | Line 20: | ||
</div> | </div> | ||
<div class="pdbe-citations 4pqw" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 4pqw" style="background-color:#fffaf0;"></div> | ||
==See Also== | |||
*[[Sodium-hydrogen exchange regulatory factor|Sodium-hydrogen exchange regulatory factor]] | |||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: | [[Category: Homo sapiens]] | ||
[[Category: Brunzelle | [[Category: Large Structures]] | ||
[[Category: Guan | [[Category: Brunzelle J]] | ||
[[Category: Holcomb | [[Category: Guan X]] | ||
[[Category: Hou | [[Category: Holcomb J]] | ||
[[Category: Jiang | [[Category: Hou Y]] | ||
[[Category: Li | [[Category: Jiang Y]] | ||
[[Category: Sirinupong | [[Category: Li C]] | ||
[[Category: Trescott | [[Category: Sirinupong N]] | ||
[[Category: Wang | [[Category: Trescott L]] | ||
[[Category: Yang | [[Category: Wang S]] | ||
[[Category: Yang Z]] | |||
Revision as of 10:25, 8 February 2023
Crystal Structure of Phospholipase C beta 3 in Complex with PDZ1 of NHERF1Crystal Structure of Phospholipase C beta 3 in Complex with PDZ1 of NHERF1
Structural highlights
DiseaseNHRF1_HUMAN Defects in SLC9A3R1 are the cause of hypophosphatemic nephrolithiasis/osteoporosis type 2 (NPHLOP2) [MIM:612287. Hypophosphatemia results from idiopathic renal phosphate loss. It contributes to the pathogenesis of hypophosphatemic urolithiasis (formation of urinary calculi) as well to that of hypophosphatemic osteoporosis (bone demineralization).[1] [2] FunctionNHRF1_HUMAN Scaffold protein that connects plasma membrane proteins with members of the ezrin/moesin/radixin family and thereby helps to link them to the actin cytoskeleton and to regulate their surface expression. Necessary for recycling of internalized ADRB2. Was first known to play a role in the regulation of the activity and subcellular location of SLC9A3. Necessary for cAMP-mediated phosphorylation and inhibition of SLC9A3. May enhance Wnt signaling. May participate in HTR4 targeting to microvilli (By similarity). Involved in the regulation of phosphate reabsorption in the renal proximal tubules.[3] [4] [5] [6] Publication Abstract from PubMedThe formation of CXCR2-NHERF1-PLCbeta3 macromolecular complex in pancreatic cancer cells regulates CXCR2 signaling activity and plays an important role in tumor proliferation and invasion. We previously have shown that disruption of the NHERF1-mediated CXCR2-PLCbeta3 interaction abolishes the CXCR2 signaling cascade and inhibits pancreatic tumor growth in vitro and in vivo. Here we report the crystal structure of the NHERF1 PDZ1 domain in complex with the C-terminal PLCbeta3 sequence. The structure reveals that the PDZ1-PLCbeta3 binding specificity is achieved by numerous hydrogen bonds and hydrophobic contacts with the last four PLCbeta3 residues contributing to specific interactions. We also show that PLCbeta3 can bind both NHERF1 PDZ1 and PDZ2 in pancreatic cancer cells, consistent with the observation that the peptide binding pockets of these PDZ domains are highly structurally conserved. This study provides an understanding of the structural basis for the PDZ-mediated NHERF1-PLCbeta3 interaction that could prove valuable in selective drug design against CXCR2-related cancers. Crystallographic analysis of NHERF1-PLCbeta3 interaction provides structural basis for CXCR2 signaling in pancreatic cancer.,Jiang Y, Wang S, Holcomb J, Trescott L, Guan X, Hou Y, Brunzelle J, Sirinupong N, Li C, Yang Z Biochem Biophys Res Commun. 2014 Mar 15. pii: S0006-291X(14)00462-8. doi:, 10.1016/j.bbrc.2014.03.028. PMID:24642259[7] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||